nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—Ethinyl Estradiol—prostate cancer	0.28	1	CrCtD
Etonogestrel—SHBG—prostate cancer	0.0782	0.495	CbGaD
Etonogestrel—ESR1—prostate cancer	0.0528	0.334	CbGaD
Etonogestrel—ESR1—Estramustine—prostate cancer	0.0333	0.161	CbGbCtD
Etonogestrel—SHBG—Estrone—prostate cancer	0.0297	0.143	CbGbCtD
Etonogestrel—CYP3A4—prostate cancer	0.027	0.171	CbGaD
Etonogestrel—SHBG—Ethinyl Estradiol—prostate cancer	0.0265	0.128	CbGbCtD
Etonogestrel—ESR1—Estrone—prostate cancer	0.0215	0.104	CbGbCtD
Etonogestrel—ESR1—Ethinyl Estradiol—prostate cancer	0.0191	0.0923	CbGbCtD
Etonogestrel—Nandrolone phenpropionate—Estradiol valerate/Dienogest—prostate cancer	0.0176	0.073	CrCrCtD
Etonogestrel—Nandrolone decanoate—Estradiol valerate/Dienogest—prostate cancer	0.0176	0.073	CrCrCtD
Etonogestrel—SHBG—Estradiol—prostate cancer	0.017	0.0822	CbGbCtD
Etonogestrel—Testosterone—Abiraterone—prostate cancer	0.0147	0.0607	CrCrCtD
Etonogestrel—ESR1—Conjugated Estrogens—prostate cancer	0.014	0.0677	CbGbCtD
Etonogestrel—Ethinyl Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.0133	0.0552	CrCrCtD
Etonogestrel—ESR1—Estradiol—prostate cancer	0.0123	0.0595	CbGbCtD
Etonogestrel—Quinestrol—Estramustine—prostate cancer	0.0119	0.0493	CrCrCtD
Etonogestrel—Mestranol—Estramustine—prostate cancer	0.0119	0.0493	CrCrCtD
Etonogestrel—Ethinyl Estradiol—Estramustine—prostate cancer	0.0113	0.047	CrCrCtD
Etonogestrel—Mestranol—Estrone—prostate cancer	0.00946	0.0392	CrCrCtD
Etonogestrel—Quinestrol—Estrone—prostate cancer	0.00946	0.0392	CrCrCtD
Etonogestrel—Desogestrel—Ethinyl Estradiol—prostate cancer	0.00944	0.0391	CrCrCtD
Etonogestrel—Ethinyl Estradiol—Estrone—prostate cancer	0.00901	0.0373	CrCrCtD
Etonogestrel—Mestranol—Conjugated Estrogens—prostate cancer	0.00833	0.0345	CrCrCtD
Etonogestrel—Quinestrol—Conjugated Estrogens—prostate cancer	0.00833	0.0345	CrCrCtD
Etonogestrel—Ethinyl Estradiol—Conjugated Estrogens—prostate cancer	0.00793	0.0328	CrCrCtD
Etonogestrel—Norelgestromin—Ethinyl Estradiol—prostate cancer	0.00737	0.0305	CrCrCtD
Etonogestrel—Quinestrol—Estradiol—prostate cancer	0.00717	0.0297	CrCrCtD
Etonogestrel—Mestranol—Estradiol—prostate cancer	0.00717	0.0297	CrCrCtD
Etonogestrel—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.007	0.0338	CbGbCtD
Etonogestrel—Quinestrol—Ethinyl Estradiol—prostate cancer	0.007	0.029	CrCrCtD
Etonogestrel—Mestranol—Ethinyl Estradiol—prostate cancer	0.007	0.029	CrCrCtD
Etonogestrel—Ethinyl Estradiol—Estradiol—prostate cancer	0.00683	0.0283	CrCrCtD
Etonogestrel—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.0061	0.0252	CrCrCtD
Etonogestrel—Testosterone—Estramustine—prostate cancer	0.00609	0.0252	CrCrCtD
Etonogestrel—Danazol—Ethinyl Estradiol—prostate cancer	0.00563	0.0233	CrCrCtD
Etonogestrel—Norethindrone—Ethinyl Estradiol—prostate cancer	0.0049	0.0203	CrCrCtD
Etonogestrel—Testosterone—Estrone—prostate cancer	0.00484	0.02	CrCrCtD
Etonogestrel—Methyltestosterone—Ethinyl Estradiol—prostate cancer	0.00402	0.0166	CrCrCtD
Etonogestrel—CYP3A4—Bicalutamide—prostate cancer	0.00368	0.0177	CbGbCtD
Etonogestrel—Testosterone—Estradiol—prostate cancer	0.00367	0.0152	CrCrCtD
Etonogestrel—CYP3A4—Estramustine—prostate cancer	0.00342	0.0165	CbGbCtD
Etonogestrel—CYP3A4—Flutamide—prostate cancer	0.00305	0.0147	CbGbCtD
Etonogestrel—CYP3A4—Abiraterone—prostate cancer	0.00305	0.0147	CbGbCtD
Etonogestrel—SHBG—semen—prostate cancer	0.00236	0.338	CbGeAlD
Etonogestrel—CYP3A4—Cabazitaxel—prostate cancer	0.00225	0.0109	CbGbCtD
Etonogestrel—CYP3A4—Estrone—prostate cancer	0.0022	0.0106	CbGbCtD
Etonogestrel—Danazol—Prednisone—prostate cancer	0.00198	0.00819	CrCrCtD
Etonogestrel—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00196	0.00948	CbGbCtD
Etonogestrel—CYP3A4—Conjugated Estrogens—prostate cancer	0.00144	0.00695	CbGbCtD
Etonogestrel—Methyltestosterone—Prednisone—prostate cancer	0.00141	0.00584	CrCrCtD
Etonogestrel—CYP3A4—Mitoxantrone—prostate cancer	0.00131	0.00632	CbGbCtD
Etonogestrel—CYP3A4—Estradiol—prostate cancer	0.00127	0.00611	CbGbCtD
Etonogestrel—CYP3A4—Prednisone—prostate cancer	0.00109	0.00525	CbGbCtD
Etonogestrel—CYP3A4—Etoposide—prostate cancer	0.000826	0.00399	CbGbCtD
Etonogestrel—CYP3A4—Docetaxel—prostate cancer	0.000756	0.00365	CbGbCtD
Etonogestrel—CYP3A4—urine—prostate cancer	0.000647	0.0928	CbGeAlD
Etonogestrel—SHBG—prostate gland—prostate cancer	0.00059	0.0848	CbGeAlD
Etonogestrel—CYP3A4—Doxorubicin—prostate cancer	0.000564	0.00272	CbGbCtD
Etonogestrel—PGR—prostate gland—prostate cancer	0.000532	0.0764	CbGeAlD
Etonogestrel—ESR1—prostate gland—prostate cancer	0.000416	0.0597	CbGeAlD
Etonogestrel—PGR—epithelium—prostate cancer	0.000391	0.0561	CbGeAlD
Etonogestrel—ESR1—epithelium—prostate cancer	0.000306	0.0439	CbGeAlD
Etonogestrel—SHBG—bone marrow—prostate cancer	0.000304	0.0437	CbGeAlD
Etonogestrel—ESR1—renal system—prostate cancer	0.000284	0.0407	CbGeAlD
Etonogestrel—SHBG—testis—prostate cancer	0.00026	0.0373	CbGeAlD
Etonogestrel—PGR—testis—prostate cancer	0.000234	0.0336	CbGeAlD
Etonogestrel—ESR1—testis—prostate cancer	0.000183	0.0263	CbGeAlD
Etonogestrel—PGR—lymph node—prostate cancer	0.00017	0.0244	CbGeAlD
Etonogestrel—CYP3A4—renal system—prostate cancer	0.000158	0.0227	CbGeAlD
Etonogestrel—Levonorgestrel—SRD5A1—prostate cancer	0.000134	0.0773	CrCbGaD
Etonogestrel—ESR1—lymph node—prostate cancer	0.000133	0.0191	CbGeAlD
Etonogestrel—Ethinyl Estradiol—AOX1—prostate cancer	0.000104	0.0596	CrCbGaD
Etonogestrel—Desogestrel—SHBG—prostate cancer	7.94e-05	0.0457	CrCbGaD
Etonogestrel—Nandrolone phenpropionate—AR—prostate cancer	7.91e-05	0.0455	CrCbGaD
Etonogestrel—Quinestrol—ESR1—prostate cancer	7.17e-05	0.0412	CrCbGaD
Etonogestrel—Gestodene—CYP3A5—prostate cancer	6.85e-05	0.0394	CrCbGaD
Etonogestrel—Nandrolone phenpropionate—CYP19A1—prostate cancer	6.62e-05	0.0381	CrCbGaD
Etonogestrel—Testosterone—CYP3A43—prostate cancer	6.45e-05	0.0371	CrCbGaD
Etonogestrel—Nandrolone decanoate—AR—prostate cancer	6e-05	0.0345	CrCbGaD
Etonogestrel—Mestranol—ESR1—prostate cancer	5.43e-05	0.0312	CrCbGaD
Etonogestrel—Desogestrel—ESR1—prostate cancer	5.37e-05	0.0309	CrCbGaD
Etonogestrel—Nandrolone decanoate—CYP19A1—prostate cancer	5.02e-05	0.0289	CrCbGaD
Etonogestrel—Norgestimate—ESR1—prostate cancer	5.02e-05	0.0289	CrCbGaD
Etonogestrel—Levonorgestrel—SHBG—prostate cancer	4.55e-05	0.0262	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ESR2—prostate cancer	4.2e-05	0.0242	CrCbGaD
Etonogestrel—Danazol—SHBG—prostate cancer	4.14e-05	0.0238	CrCbGaD
Etonogestrel—Levonorgestrel—AR—prostate cancer	3.99e-05	0.0229	CrCbGaD
Etonogestrel—Ethinyl Estradiol—SHBG—prostate cancer	3.83e-05	0.022	CrCbGaD
Etonogestrel—Norethindrone—SHBG—prostate cancer	3.69e-05	0.0212	CrCbGaD
Etonogestrel—Danazol—AR—prostate cancer	3.63e-05	0.0209	CrCbGaD
Etonogestrel—Methyltestosterone—SHBG—prostate cancer	3.5e-05	0.0201	CrCbGaD
Etonogestrel—Levonorgestrel—CYP19A1—prostate cancer	3.34e-05	0.0192	CrCbGaD
Etonogestrel—Levonorgestrel—ESR1—prostate cancer	3.07e-05	0.0177	CrCbGaD
Etonogestrel—Methyltestosterone—AR—prostate cancer	3.07e-05	0.0176	CrCbGaD
Etonogestrel—Danazol—CYP19A1—prostate cancer	3.04e-05	0.0175	CrCbGaD
Etonogestrel—Norethindrone—CYP3A5—prostate cancer	2.94e-05	0.0169	CrCbGaD
Etonogestrel—Danazol—ESR1—prostate cancer	2.8e-05	0.0161	CrCbGaD
Etonogestrel—Testosterone—SLC22A3—prostate cancer	2.79e-05	0.0161	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ESR1—prostate cancer	2.59e-05	0.0149	CrCbGaD
Etonogestrel—Methyltestosterone—CYP19A1—prostate cancer	2.57e-05	0.0148	CrCbGaD
Etonogestrel—Testosterone—SHBG—prostate cancer	2.03e-05	0.0117	CrCbGaD
Etonogestrel—Testosterone—CYP1B1—prostate cancer	2.03e-05	0.0117	CrCbGaD
Etonogestrel—Testosterone—SLC22A1—prostate cancer	2e-05	0.0115	CrCbGaD
Etonogestrel—Norethindrone—CYP2C19—prostate cancer	2e-05	0.0115	CrCbGaD
Etonogestrel—Testosterone—AR—prostate cancer	1.78e-05	0.0102	CrCbGaD
Etonogestrel—Testosterone—CYP3A5—prostate cancer	1.62e-05	0.0093	CrCbGaD
Etonogestrel—Levonorgestrel—CYP3A4—prostate cancer	1.57e-05	0.00902	CrCbGaD
Etonogestrel—Testosterone—CYP19A1—prostate cancer	1.49e-05	0.00857	CrCbGaD
Etonogestrel—Danazol—CYP3A4—prostate cancer	1.43e-05	0.00821	CrCbGaD
Etonogestrel—Ethinyl Estradiol—CYP3A4—prostate cancer	1.32e-05	0.0076	CrCbGaD
Etonogestrel—Norethindrone—CYP3A4—prostate cancer	1.27e-05	0.00731	CrCbGaD
Etonogestrel—Methyltestosterone—CYP3A4—prostate cancer	1.21e-05	0.00694	CrCbGaD
Etonogestrel—Testosterone—CYP2C19—prostate cancer	1.1e-05	0.00633	CrCbGaD
Etonogestrel—Testosterone—CYP1A1—prostate cancer	1.1e-05	0.0063	CrCbGaD
Etonogestrel—Sinusitis—Epirubicin—prostate cancer	8.33e-06	0.000104	CcSEcCtD
Etonogestrel—Feeling abnormal—Etoposide—prostate cancer	8.33e-06	0.000104	CcSEcCtD
Etonogestrel—Diarrhoea—Mitoxantrone—prostate cancer	8.31e-06	0.000104	CcSEcCtD
Etonogestrel—Vomiting—Estradiol—prostate cancer	8.29e-06	0.000104	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Etoposide—prostate cancer	8.26e-06	0.000103	CcSEcCtD
Etonogestrel—Nervous system disorder—Docetaxel—prostate cancer	8.23e-06	0.000103	CcSEcCtD
Etonogestrel—Ill-defined disorder—Prednisone—prostate cancer	8.23e-06	0.000103	CcSEcCtD
Etonogestrel—Rash—Estradiol—prostate cancer	8.22e-06	0.000103	CcSEcCtD
Etonogestrel—Infestation NOS—Doxorubicin—prostate cancer	8.22e-06	0.000103	CcSEcCtD
Etonogestrel—Infestation—Doxorubicin—prostate cancer	8.22e-06	0.000103	CcSEcCtD
Etonogestrel—Dermatitis—Estradiol—prostate cancer	8.21e-06	0.000103	CcSEcCtD
Etonogestrel—Headache—Estradiol—prostate cancer	8.17e-06	0.000102	CcSEcCtD
Etonogestrel—Skin disorder—Docetaxel—prostate cancer	8.16e-06	0.000102	CcSEcCtD
Etonogestrel—Oedema—Capecitabine—prostate cancer	8.13e-06	0.000102	CcSEcCtD
Etonogestrel—Angioedema—Prednisone—prostate cancer	8.11e-06	0.000101	CcSEcCtD
Etonogestrel—Infection—Capecitabine—prostate cancer	8.08e-06	0.000101	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Doxorubicin—prostate cancer	8.05e-06	0.000101	CcSEcCtD
Etonogestrel—Urticaria—Etoposide—prostate cancer	8.03e-06	0.0001	CcSEcCtD
Etonogestrel—Haemoglobin—Epirubicin—prostate cancer	8.01e-06	0.0001	CcSEcCtD
Etonogestrel—Anorexia—Docetaxel—prostate cancer	8e-06	0.0001	CcSEcCtD
Etonogestrel—Malaise—Prednisone—prostate cancer	8e-06	0.0001	CcSEcCtD
Etonogestrel—Rhinitis—Epirubicin—prostate cancer	7.99e-06	9.99e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Etoposide—prostate cancer	7.99e-06	9.98e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Etoposide—prostate cancer	7.99e-06	9.98e-05	CcSEcCtD
Etonogestrel—Urinary tract infection—Doxorubicin—prostate cancer	7.99e-06	9.98e-05	CcSEcCtD
Etonogestrel—Nervous system disorder—Capecitabine—prostate cancer	7.97e-06	9.96e-05	CcSEcCtD
Etonogestrel—Haemorrhage—Epirubicin—prostate cancer	7.97e-06	9.96e-05	CcSEcCtD
Etonogestrel—Hypoaesthesia—Epirubicin—prostate cancer	7.93e-06	9.91e-05	CcSEcCtD
Etonogestrel—Pharyngitis—Epirubicin—prostate cancer	7.91e-06	9.89e-05	CcSEcCtD
Etonogestrel—Skin disorder—Capecitabine—prostate cancer	7.9e-06	9.87e-05	CcSEcCtD
Etonogestrel—Urinary tract disorder—Epirubicin—prostate cancer	7.87e-06	9.84e-05	CcSEcCtD
Etonogestrel—Connective tissue disorder—Epirubicin—prostate cancer	7.83e-06	9.79e-05	CcSEcCtD
Etonogestrel—Urethral disorder—Epirubicin—prostate cancer	7.81e-06	9.76e-05	CcSEcCtD
Etonogestrel—Anorexia—Capecitabine—prostate cancer	7.75e-06	9.68e-05	CcSEcCtD
Etonogestrel—Nausea—Estradiol—prostate cancer	7.74e-06	9.68e-05	CcSEcCtD
Etonogestrel—Vomiting—Mitoxantrone—prostate cancer	7.72e-06	9.65e-05	CcSEcCtD
Etonogestrel—Sinusitis—Doxorubicin—prostate cancer	7.71e-06	9.63e-05	CcSEcCtD
Etonogestrel—Convulsion—Prednisone—prostate cancer	7.69e-06	9.61e-05	CcSEcCtD
Etonogestrel—Visual impairment—Epirubicin—prostate cancer	7.68e-06	9.6e-05	CcSEcCtD
Etonogestrel—Hypertension—Prednisone—prostate cancer	7.66e-06	9.57e-05	CcSEcCtD
Etonogestrel—Rash—Mitoxantrone—prostate cancer	7.66e-06	9.57e-05	CcSEcCtD
Etonogestrel—Dermatitis—Mitoxantrone—prostate cancer	7.65e-06	9.56e-05	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.65e-06	9.56e-05	CcSEcCtD
Etonogestrel—Headache—Mitoxantrone—prostate cancer	7.61e-06	9.51e-05	CcSEcCtD
Etonogestrel—Insomnia—Docetaxel—prostate cancer	7.59e-06	9.49e-05	CcSEcCtD
Etonogestrel—Myalgia—Prednisone—prostate cancer	7.55e-06	9.44e-05	CcSEcCtD
Etonogestrel—Arthralgia—Prednisone—prostate cancer	7.55e-06	9.44e-05	CcSEcCtD
Etonogestrel—Paraesthesia—Docetaxel—prostate cancer	7.54e-06	9.42e-05	CcSEcCtD
Etonogestrel—Anxiety—Prednisone—prostate cancer	7.53e-06	9.41e-05	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.5e-06	9.37e-05	CcSEcCtD
Etonogestrel—Somnolence—Docetaxel—prostate cancer	7.46e-06	9.33e-05	CcSEcCtD
Etonogestrel—Discomfort—Prednisone—prostate cancer	7.46e-06	9.33e-05	CcSEcCtD
Etonogestrel—Eye disorder—Epirubicin—prostate cancer	7.45e-06	9.31e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Etoposide—prostate cancer	7.44e-06	9.3e-05	CcSEcCtD
Etonogestrel—Haemoglobin—Doxorubicin—prostate cancer	7.41e-06	9.26e-05	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.41e-06	9.26e-05	CcSEcCtD
Etonogestrel—Rhinitis—Doxorubicin—prostate cancer	7.39e-06	9.24e-05	CcSEcCtD
Etonogestrel—Dyspepsia—Docetaxel—prostate cancer	7.39e-06	9.24e-05	CcSEcCtD
Etonogestrel—Haemorrhage—Doxorubicin—prostate cancer	7.38e-06	9.22e-05	CcSEcCtD
Etonogestrel—Insomnia—Capecitabine—prostate cancer	7.35e-06	9.19e-05	CcSEcCtD
Etonogestrel—Hypoaesthesia—Doxorubicin—prostate cancer	7.34e-06	9.17e-05	CcSEcCtD
Etonogestrel—Pharyngitis—Doxorubicin—prostate cancer	7.32e-06	9.15e-05	CcSEcCtD
Etonogestrel—Paraesthesia—Capecitabine—prostate cancer	7.3e-06	9.12e-05	CcSEcCtD
Etonogestrel—Decreased appetite—Docetaxel—prostate cancer	7.3e-06	9.12e-05	CcSEcCtD
Etonogestrel—Urinary tract disorder—Doxorubicin—prostate cancer	7.28e-06	9.1e-05	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Docetaxel—prostate cancer	7.25e-06	9.06e-05	CcSEcCtD
Etonogestrel—Asthenia—Etoposide—prostate cancer	7.25e-06	9.06e-05	CcSEcCtD
Etonogestrel—Connective tissue disorder—Doxorubicin—prostate cancer	7.25e-06	9.06e-05	CcSEcCtD
Etonogestrel—Anaphylactic shock—Prednisone—prostate cancer	7.24e-06	9.05e-05	CcSEcCtD
Etonogestrel—Oedema—Prednisone—prostate cancer	7.24e-06	9.05e-05	CcSEcCtD
Etonogestrel—Fatigue—Docetaxel—prostate cancer	7.24e-06	9.05e-05	CcSEcCtD
Etonogestrel—Angiopathy—Epirubicin—prostate cancer	7.23e-06	9.04e-05	CcSEcCtD
Etonogestrel—Urethral disorder—Doxorubicin—prostate cancer	7.23e-06	9.04e-05	CcSEcCtD
Etonogestrel—Nausea—Mitoxantrone—prostate cancer	7.22e-06	9.02e-05	CcSEcCtD
Etonogestrel—Immune system disorder—Epirubicin—prostate cancer	7.2e-06	9e-05	CcSEcCtD
Etonogestrel—Infection—Prednisone—prostate cancer	7.19e-06	8.99e-05	CcSEcCtD
Etonogestrel—Constipation—Docetaxel—prostate cancer	7.18e-06	8.97e-05	CcSEcCtD
Etonogestrel—Pain—Docetaxel—prostate cancer	7.18e-06	8.97e-05	CcSEcCtD
Etonogestrel—Dyspepsia—Capecitabine—prostate cancer	7.16e-06	8.94e-05	CcSEcCtD
Etonogestrel—Pruritus—Etoposide—prostate cancer	7.15e-06	8.93e-05	CcSEcCtD
Etonogestrel—Visual impairment—Doxorubicin—prostate cancer	7.11e-06	8.88e-05	CcSEcCtD
Etonogestrel—Nervous system disorder—Prednisone—prostate cancer	7.1e-06	8.87e-05	CcSEcCtD
Etonogestrel—Decreased appetite—Capecitabine—prostate cancer	7.07e-06	8.83e-05	CcSEcCtD
Etonogestrel—Alopecia—Epirubicin—prostate cancer	7.04e-06	8.8e-05	CcSEcCtD
Etonogestrel—Skin disorder—Prednisone—prostate cancer	7.03e-06	8.79e-05	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Capecitabine—prostate cancer	7.02e-06	8.77e-05	CcSEcCtD
Etonogestrel—Fatigue—Capecitabine—prostate cancer	7.01e-06	8.76e-05	CcSEcCtD
Etonogestrel—Testosterone—CYP3A4—prostate cancer	7e-06	0.00402	CrCbGaD
Etonogestrel—Mental disorder—Epirubicin—prostate cancer	6.98e-06	8.73e-05	CcSEcCtD
Etonogestrel—Pain—Capecitabine—prostate cancer	6.95e-06	8.69e-05	CcSEcCtD
Etonogestrel—Constipation—Capecitabine—prostate cancer	6.95e-06	8.69e-05	CcSEcCtD
Etonogestrel—Erythema—Epirubicin—prostate cancer	6.94e-06	8.67e-05	CcSEcCtD
Etonogestrel—Malnutrition—Epirubicin—prostate cancer	6.94e-06	8.67e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Docetaxel—prostate cancer	6.92e-06	8.65e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Etoposide—prostate cancer	6.91e-06	8.64e-05	CcSEcCtD
Etonogestrel—Anorexia—Prednisone—prostate cancer	6.9e-06	8.63e-05	CcSEcCtD
Etonogestrel—Eye disorder—Doxorubicin—prostate cancer	6.89e-06	8.61e-05	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Docetaxel—prostate cancer	6.87e-06	8.58e-05	CcSEcCtD
Etonogestrel—Flatulence—Epirubicin—prostate cancer	6.84e-06	8.55e-05	CcSEcCtD
Etonogestrel—Tension—Epirubicin—prostate cancer	6.81e-06	8.51e-05	CcSEcCtD
Etonogestrel—Nervousness—Epirubicin—prostate cancer	6.74e-06	8.42e-05	CcSEcCtD
Etonogestrel—Back pain—Epirubicin—prostate cancer	6.71e-06	8.39e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Capecitabine—prostate cancer	6.7e-06	8.37e-05	CcSEcCtD
Etonogestrel—Angiopathy—Doxorubicin—prostate cancer	6.69e-06	8.36e-05	CcSEcCtD
Etonogestrel—Dizziness—Etoposide—prostate cancer	6.68e-06	8.35e-05	CcSEcCtD
Etonogestrel—Muscle spasms—Epirubicin—prostate cancer	6.67e-06	8.34e-05	CcSEcCtD
Etonogestrel—Immune system disorder—Doxorubicin—prostate cancer	6.66e-06	8.33e-05	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Capecitabine—prostate cancer	6.65e-06	8.31e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Docetaxel—prostate cancer	6.64e-06	8.29e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Docetaxel—prostate cancer	6.64e-06	8.29e-05	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Prednisone—prostate cancer	6.6e-06	8.24e-05	CcSEcCtD
Etonogestrel—Insomnia—Prednisone—prostate cancer	6.55e-06	8.18e-05	CcSEcCtD
Etonogestrel—Alopecia—Doxorubicin—prostate cancer	6.52e-06	8.14e-05	CcSEcCtD
Etonogestrel—Paraesthesia—Prednisone—prostate cancer	6.5e-06	8.13e-05	CcSEcCtD
Etonogestrel—Mental disorder—Doxorubicin—prostate cancer	6.46e-06	8.08e-05	CcSEcCtD
Etonogestrel—Urticaria—Capecitabine—prostate cancer	6.46e-06	8.07e-05	CcSEcCtD
Etonogestrel—Ill-defined disorder—Epirubicin—prostate cancer	6.44e-06	8.05e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Capecitabine—prostate cancer	6.43e-06	8.03e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Capecitabine—prostate cancer	6.43e-06	8.03e-05	CcSEcCtD
Etonogestrel—Vomiting—Etoposide—prostate cancer	6.42e-06	8.03e-05	CcSEcCtD
Etonogestrel—Erythema—Doxorubicin—prostate cancer	6.42e-06	8.02e-05	CcSEcCtD
Etonogestrel—Malnutrition—Doxorubicin—prostate cancer	6.42e-06	8.02e-05	CcSEcCtD
Etonogestrel—Dyspepsia—Prednisone—prostate cancer	6.37e-06	7.97e-05	CcSEcCtD
Etonogestrel—Rash—Etoposide—prostate cancer	6.37e-06	7.96e-05	CcSEcCtD
Etonogestrel—Dermatitis—Etoposide—prostate cancer	6.36e-06	7.95e-05	CcSEcCtD
Etonogestrel—Headache—Etoposide—prostate cancer	6.33e-06	7.91e-05	CcSEcCtD
Etonogestrel—Flatulence—Doxorubicin—prostate cancer	6.33e-06	7.91e-05	CcSEcCtD
Etonogestrel—Tension—Doxorubicin—prostate cancer	6.3e-06	7.87e-05	CcSEcCtD
Etonogestrel—Decreased appetite—Prednisone—prostate cancer	6.3e-06	7.87e-05	CcSEcCtD
Etonogestrel—Malaise—Epirubicin—prostate cancer	6.26e-06	7.82e-05	CcSEcCtD
Etonogestrel—Fatigue—Prednisone—prostate cancer	6.24e-06	7.8e-05	CcSEcCtD
Etonogestrel—Nervousness—Doxorubicin—prostate cancer	6.24e-06	7.79e-05	CcSEcCtD
Etonogestrel—Back pain—Doxorubicin—prostate cancer	6.21e-06	7.76e-05	CcSEcCtD
Etonogestrel—Constipation—Prednisone—prostate cancer	6.19e-06	7.74e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Docetaxel—prostate cancer	6.19e-06	7.73e-05	CcSEcCtD
Etonogestrel—Muscle spasms—Doxorubicin—prostate cancer	6.17e-06	7.71e-05	CcSEcCtD
Etonogestrel—Cough—Epirubicin—prostate cancer	6.06e-06	7.57e-05	CcSEcCtD
Etonogestrel—Asthenia—Docetaxel—prostate cancer	6.02e-06	7.53e-05	CcSEcCtD
Etonogestrel—Convulsion—Epirubicin—prostate cancer	6.01e-06	7.51e-05	CcSEcCtD
Etonogestrel—Nausea—Etoposide—prostate cancer	6e-06	7.5e-05	CcSEcCtD
Etonogestrel—Hypertension—Epirubicin—prostate cancer	5.99e-06	7.49e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Capecitabine—prostate cancer	5.99e-06	7.48e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Prednisone—prostate cancer	5.97e-06	7.46e-05	CcSEcCtD
Etonogestrel—Ill-defined disorder—Doxorubicin—prostate cancer	5.96e-06	7.44e-05	CcSEcCtD
Etonogestrel—Pruritus—Docetaxel—prostate cancer	5.94e-06	7.42e-05	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Prednisone—prostate cancer	5.92e-06	7.4e-05	CcSEcCtD
Etonogestrel—Myalgia—Epirubicin—prostate cancer	5.91e-06	7.38e-05	CcSEcCtD
Etonogestrel—Arthralgia—Epirubicin—prostate cancer	5.91e-06	7.38e-05	CcSEcCtD
Etonogestrel—Anxiety—Epirubicin—prostate cancer	5.89e-06	7.36e-05	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.87e-06	7.33e-05	CcSEcCtD
Etonogestrel—Discomfort—Epirubicin—prostate cancer	5.84e-06	7.29e-05	CcSEcCtD
Etonogestrel—Asthenia—Capecitabine—prostate cancer	5.83e-06	7.29e-05	CcSEcCtD
Etonogestrel—Malaise—Doxorubicin—prostate cancer	5.79e-06	7.24e-05	CcSEcCtD
Etonogestrel—Urticaria—Prednisone—prostate cancer	5.75e-06	7.19e-05	CcSEcCtD
Etonogestrel—Pruritus—Capecitabine—prostate cancer	5.75e-06	7.19e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Docetaxel—prostate cancer	5.75e-06	7.18e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Prednisone—prostate cancer	5.72e-06	7.15e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Prednisone—prostate cancer	5.72e-06	7.15e-05	CcSEcCtD
Etonogestrel—Anaphylactic shock—Epirubicin—prostate cancer	5.66e-06	7.08e-05	CcSEcCtD
Etonogestrel—Oedema—Epirubicin—prostate cancer	5.66e-06	7.08e-05	CcSEcCtD
Etonogestrel—Infection—Epirubicin—prostate cancer	5.63e-06	7.03e-05	CcSEcCtD
Etonogestrel—Cough—Doxorubicin—prostate cancer	5.6e-06	7e-05	CcSEcCtD
Etonogestrel—Convulsion—Doxorubicin—prostate cancer	5.56e-06	6.95e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Capecitabine—prostate cancer	5.56e-06	6.95e-05	CcSEcCtD
Etonogestrel—Nervous system disorder—Epirubicin—prostate cancer	5.55e-06	6.94e-05	CcSEcCtD
Etonogestrel—Dizziness—Docetaxel—prostate cancer	5.55e-06	6.94e-05	CcSEcCtD
Etonogestrel—Hypertension—Doxorubicin—prostate cancer	5.54e-06	6.93e-05	CcSEcCtD
Etonogestrel—Skin disorder—Epirubicin—prostate cancer	5.5e-06	6.87e-05	CcSEcCtD
Etonogestrel—Myalgia—Doxorubicin—prostate cancer	5.47e-06	6.83e-05	CcSEcCtD
Etonogestrel—Arthralgia—Doxorubicin—prostate cancer	5.47e-06	6.83e-05	CcSEcCtD
Etonogestrel—Anxiety—Doxorubicin—prostate cancer	5.45e-06	6.81e-05	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.43e-06	6.78e-05	CcSEcCtD
Etonogestrel—Discomfort—Doxorubicin—prostate cancer	5.4e-06	6.75e-05	CcSEcCtD
Etonogestrel—Anorexia—Epirubicin—prostate cancer	5.4e-06	6.75e-05	CcSEcCtD
Etonogestrel—Dizziness—Capecitabine—prostate cancer	5.38e-06	6.72e-05	CcSEcCtD
Etonogestrel—Vomiting—Docetaxel—prostate cancer	5.34e-06	6.67e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Prednisone—prostate cancer	5.34e-06	6.67e-05	CcSEcCtD
Etonogestrel—Rash—Docetaxel—prostate cancer	5.29e-06	6.62e-05	CcSEcCtD
Etonogestrel—Dermatitis—Docetaxel—prostate cancer	5.29e-06	6.61e-05	CcSEcCtD
Etonogestrel—Headache—Docetaxel—prostate cancer	5.26e-06	6.57e-05	CcSEcCtD
Etonogestrel—Oedema—Doxorubicin—prostate cancer	5.24e-06	6.55e-05	CcSEcCtD
Etonogestrel—Anaphylactic shock—Doxorubicin—prostate cancer	5.24e-06	6.55e-05	CcSEcCtD
Etonogestrel—Infection—Doxorubicin—prostate cancer	5.21e-06	6.51e-05	CcSEcCtD
Etonogestrel—Asthenia—Prednisone—prostate cancer	5.2e-06	6.49e-05	CcSEcCtD
Etonogestrel—Vomiting—Capecitabine—prostate cancer	5.17e-06	6.46e-05	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.16e-06	6.45e-05	CcSEcCtD
Etonogestrel—Nervous system disorder—Doxorubicin—prostate cancer	5.14e-06	6.42e-05	CcSEcCtD
Etonogestrel—Rash—Capecitabine—prostate cancer	5.13e-06	6.41e-05	CcSEcCtD
Etonogestrel—Pruritus—Prednisone—prostate cancer	5.12e-06	6.4e-05	CcSEcCtD
Etonogestrel—Insomnia—Epirubicin—prostate cancer	5.12e-06	6.4e-05	CcSEcCtD
Etonogestrel—Dermatitis—Capecitabine—prostate cancer	5.12e-06	6.4e-05	CcSEcCtD
Etonogestrel—Headache—Capecitabine—prostate cancer	5.09e-06	6.36e-05	CcSEcCtD
Etonogestrel—Skin disorder—Doxorubicin—prostate cancer	5.09e-06	6.36e-05	CcSEcCtD
Etonogestrel—Paraesthesia—Epirubicin—prostate cancer	5.09e-06	6.36e-05	CcSEcCtD
Etonogestrel—Somnolence—Epirubicin—prostate cancer	5.04e-06	6.29e-05	CcSEcCtD
Etonogestrel—Anorexia—Doxorubicin—prostate cancer	5e-06	6.24e-05	CcSEcCtD
Etonogestrel—Nausea—Docetaxel—prostate cancer	4.99e-06	6.23e-05	CcSEcCtD
Etonogestrel—Dyspepsia—Epirubicin—prostate cancer	4.99e-06	6.23e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Prednisone—prostate cancer	4.95e-06	6.19e-05	CcSEcCtD
Etonogestrel—Decreased appetite—Epirubicin—prostate cancer	4.92e-06	6.15e-05	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Epirubicin—prostate cancer	4.89e-06	6.11e-05	CcSEcCtD
Etonogestrel—Fatigue—Epirubicin—prostate cancer	4.88e-06	6.1e-05	CcSEcCtD
Etonogestrel—Pain—Epirubicin—prostate cancer	4.84e-06	6.05e-05	CcSEcCtD
Etonogestrel—Constipation—Epirubicin—prostate cancer	4.84e-06	6.05e-05	CcSEcCtD
Etonogestrel—Nausea—Capecitabine—prostate cancer	4.83e-06	6.03e-05	CcSEcCtD
Etonogestrel—Dizziness—Prednisone—prostate cancer	4.79e-06	5.98e-05	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.77e-06	5.97e-05	CcSEcCtD
Etonogestrel—Insomnia—Doxorubicin—prostate cancer	4.74e-06	5.92e-05	CcSEcCtD
Etonogestrel—Paraesthesia—Doxorubicin—prostate cancer	4.71e-06	5.88e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Epirubicin—prostate cancer	4.67e-06	5.83e-05	CcSEcCtD
Etonogestrel—Somnolence—Doxorubicin—prostate cancer	4.66e-06	5.82e-05	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Epirubicin—prostate cancer	4.63e-06	5.79e-05	CcSEcCtD
Etonogestrel—Dyspepsia—Doxorubicin—prostate cancer	4.61e-06	5.76e-05	CcSEcCtD
Etonogestrel—Vomiting—Prednisone—prostate cancer	4.6e-06	5.75e-05	CcSEcCtD
Etonogestrel—Rash—Prednisone—prostate cancer	4.57e-06	5.71e-05	CcSEcCtD
Etonogestrel—Dermatitis—Prednisone—prostate cancer	4.56e-06	5.7e-05	CcSEcCtD
Etonogestrel—Decreased appetite—Doxorubicin—prostate cancer	4.56e-06	5.69e-05	CcSEcCtD
Etonogestrel—Headache—Prednisone—prostate cancer	4.54e-06	5.67e-05	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.52e-06	5.65e-05	CcSEcCtD
Etonogestrel—Fatigue—Doxorubicin—prostate cancer	4.52e-06	5.65e-05	CcSEcCtD
Etonogestrel—Urticaria—Epirubicin—prostate cancer	4.5e-06	5.62e-05	CcSEcCtD
Etonogestrel—Pain—Doxorubicin—prostate cancer	4.48e-06	5.6e-05	CcSEcCtD
Etonogestrel—Constipation—Doxorubicin—prostate cancer	4.48e-06	5.6e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Epirubicin—prostate cancer	4.48e-06	5.59e-05	CcSEcCtD
Etonogestrel—Body temperature increased—Epirubicin—prostate cancer	4.48e-06	5.59e-05	CcSEcCtD
Etonogestrel—Feeling abnormal—Doxorubicin—prostate cancer	4.32e-06	5.4e-05	CcSEcCtD
Etonogestrel—Nausea—Prednisone—prostate cancer	4.3e-06	5.38e-05	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Doxorubicin—prostate cancer	4.29e-06	5.35e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Epirubicin—prostate cancer	4.17e-06	5.21e-05	CcSEcCtD
Etonogestrel—Urticaria—Doxorubicin—prostate cancer	4.16e-06	5.2e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—P4HB—prostate cancer	4.16e-06	0.000174	CbGpPWpGaD
Etonogestrel—Body temperature increased—Doxorubicin—prostate cancer	4.14e-06	5.18e-05	CcSEcCtD
Etonogestrel—Abdominal pain—Doxorubicin—prostate cancer	4.14e-06	5.18e-05	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—VAV3—prostate cancer	4.11e-06	0.000172	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HIST1H2BG—prostate cancer	4.08e-06	0.00017	CbGpPWpGaD
Etonogestrel—Asthenia—Epirubicin—prostate cancer	4.06e-06	5.08e-05	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—TGFBR2—prostate cancer	4.05e-06	0.000169	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PDE4D—prostate cancer	4.05e-06	0.000169	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GRB7—prostate cancer	4.05e-06	0.000169	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—NCOA1—prostate cancer	4.01e-06	0.000167	CbGpPWpGaD
Etonogestrel—Pruritus—Epirubicin—prostate cancer	4.01e-06	5.01e-05	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—ITPR1—prostate cancer	3.99e-06	0.000166	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.98e-06	0.000166	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HIST1H4H—prostate cancer	3.94e-06	0.000165	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—CREBBP—prostate cancer	3.94e-06	0.000164	CbGpPWpGaD
Etonogestrel—Diarrhoea—Epirubicin—prostate cancer	3.88e-06	4.84e-05	CcSEcCtD
Etonogestrel—Hypersensitivity—Doxorubicin—prostate cancer	3.86e-06	4.82e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—GNG5—prostate cancer	3.85e-06	0.000161	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—AR—prostate cancer	3.84e-06	0.00016	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—RXRA—prostate cancer	3.81e-06	0.000159	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IGF1R—prostate cancer	3.81e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GRHL1—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CBR1—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ADI1—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PSAT1—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TST—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CSAD—prostate cancer	3.8e-06	0.000159	CbGpPWpGaD
Etonogestrel—Asthenia—Doxorubicin—prostate cancer	3.76e-06	4.7e-05	CcSEcCtD
Etonogestrel—Dizziness—Epirubicin—prostate cancer	3.75e-06	4.68e-05	CcSEcCtD
Etonogestrel—Pruritus—Doxorubicin—prostate cancer	3.71e-06	4.63e-05	CcSEcCtD
Etonogestrel—PGR—Gene Expression—SERPINE1—prostate cancer	3.7e-06	0.000154	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—LPL—prostate cancer	3.65e-06	0.000152	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PDGFRB—prostate cancer	3.62e-06	0.000151	CbGpPWpGaD
Etonogestrel—Vomiting—Epirubicin—prostate cancer	3.6e-06	4.5e-05	CcSEcCtD
Etonogestrel—Diarrhoea—Doxorubicin—prostate cancer	3.59e-06	4.48e-05	CcSEcCtD
Etonogestrel—Rash—Epirubicin—prostate cancer	3.57e-06	4.46e-05	CcSEcCtD
Etonogestrel—Dermatitis—Epirubicin—prostate cancer	3.57e-06	4.46e-05	CcSEcCtD
Etonogestrel—Headache—Epirubicin—prostate cancer	3.55e-06	4.43e-05	CcSEcCtD
Etonogestrel—CYP3A4—Metabolism—GRHPR—prostate cancer	3.53e-06	0.000147	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—UGT2B15—prostate cancer	3.53e-06	0.000147	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—UGT2B17—prostate cancer	3.53e-06	0.000147	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CKMT2—prostate cancer	3.53e-06	0.000147	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ITGB3—prostate cancer	3.53e-06	0.000147	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—SIRT1—prostate cancer	3.51e-06	0.000146	CbGpPWpGaD
Etonogestrel—Dizziness—Doxorubicin—prostate cancer	3.47e-06	4.33e-05	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—VDR—prostate cancer	3.45e-06	0.000144	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ERBB3—prostate cancer	3.42e-06	0.000143	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—FGFR2—prostate cancer	3.42e-06	0.000143	CbGpPWpGaD
Etonogestrel—Nausea—Epirubicin—prostate cancer	3.36e-06	4.2e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—PTHLH—prostate cancer	3.35e-06	0.00014	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFBR1—prostate cancer	3.35e-06	0.00014	CbGpPWpGaD
Etonogestrel—Vomiting—Doxorubicin—prostate cancer	3.33e-06	4.16e-05	CcSEcCtD
Etonogestrel—CYP3A4—Metabolism—RFK—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PGAM2—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MBTPS1—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AOX1—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTM3—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SULT2B1—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NAGLU—prostate cancer	3.32e-06	0.000139	CbGpPWpGaD
Etonogestrel—Rash—Doxorubicin—prostate cancer	3.3e-06	4.13e-05	CcSEcCtD
Etonogestrel—Dermatitis—Doxorubicin—prostate cancer	3.3e-06	4.13e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—AKR1C3—prostate cancer	3.3e-06	0.000138	CbGpPWpGaD
Etonogestrel—Headache—Doxorubicin—prostate cancer	3.28e-06	4.1e-05	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—PRKACB—prostate cancer	3.28e-06	0.000137	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TERT—prostate cancer	3.28e-06	0.000137	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—THBS1—prostate cancer	3.2e-06	0.000133	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PPP3CA—prostate cancer	3.2e-06	0.000133	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—ERCC2—prostate cancer	3.16e-06	0.000132	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ANXA1—prostate cancer	3.15e-06	0.000132	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—DEGS1—prostate cancer	3.15e-06	0.000131	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP3A43—prostate cancer	3.15e-06	0.000131	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NAT1—prostate cancer	3.15e-06	0.000131	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SRD5A2—prostate cancer	3.15e-06	0.000131	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AMACR—prostate cancer	3.15e-06	0.000131	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HIF1A—prostate cancer	3.14e-06	0.000131	CbGpPWpGaD
Etonogestrel—Nausea—Doxorubicin—prostate cancer	3.11e-06	3.89e-05	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—NR3C1—prostate cancer	3.11e-06	0.00013	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PRKCZ—prostate cancer	3.09e-06	0.000129	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—LEP—prostate cancer	3.06e-06	0.000128	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CAV1—prostate cancer	3.03e-06	0.000127	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HSD17B1—prostate cancer	3e-06	0.000125	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KDR—prostate cancer	3e-06	0.000125	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGFR4—prostate cancer	2.99e-06	0.000125	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PARP1—prostate cancer	2.99e-06	0.000125	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CALCA—prostate cancer	2.95e-06	0.000123	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ESR1—prostate cancer	2.92e-06	0.000122	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—PPARA—prostate cancer	2.91e-06	0.000122	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL12—prostate cancer	2.88e-06	0.00012	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—BAD—prostate cancer	2.85e-06	0.000119	CbGpPWpGaD
Etonogestrel—ESR1—Generic Transcription Pathway—MYC—prostate cancer	2.85e-06	0.000119	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CG—prostate cancer	2.76e-06	0.000115	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—APC—prostate cancer	2.76e-06	0.000115	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IRS1—prostate cancer	2.73e-06	0.000114	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGF—prostate cancer	2.73e-06	0.000114	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CASP9—prostate cancer	2.72e-06	0.000113	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HPGD—prostate cancer	2.68e-06	0.000112	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—B4GALT4—prostate cancer	2.68e-06	0.000112	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—GSK3B—prostate cancer	2.65e-06	0.000111	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PRKCQ—prostate cancer	2.63e-06	0.00011	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NGFR—prostate cancer	2.63e-06	0.00011	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—INS—prostate cancer	2.62e-06	0.000109	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAP3K7—prostate cancer	2.6e-06	0.000108	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CREBBP—prostate cancer	2.56e-06	0.000107	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IGF1—prostate cancer	2.53e-06	0.000106	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TNFRSF21—prostate cancer	2.52e-06	0.000105	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF10—prostate cancer	2.5e-06	0.000104	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ADRB2—prostate cancer	2.47e-06	0.000103	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP7B1—prostate cancer	2.45e-06	0.000102	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MTAP—prostate cancer	2.45e-06	0.000102	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MAP2K1—prostate cancer	2.45e-06	0.000102	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CD—prostate cancer	2.43e-06	0.000101	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—VAV3—prostate cancer	2.41e-06	0.000101	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SERPINE1—prostate cancer	2.4e-06	0.0001	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SULT1E1—prostate cancer	2.39e-06	9.95e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SRD5A1—prostate cancer	2.39e-06	9.95e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFBR2—prostate cancer	2.38e-06	9.92e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ITPR1—prostate cancer	2.34e-06	9.76e-05	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—MYC—prostate cancer	2.34e-06	9.76e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—FGF2—prostate cancer	2.33e-06	9.71e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—CREBBP—prostate cancer	2.31e-06	9.65e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NOS3—prostate cancer	2.29e-06	9.58e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HSD17B3—prostate cancer	2.28e-06	9.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ACSL4—prostate cancer	2.28e-06	9.5e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IGF1R—prostate cancer	2.24e-06	9.33e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—JAK2—prostate cancer	2.23e-06	9.31e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PHGDH—prostate cancer	2.18e-06	9.1e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—UMPS—prostate cancer	2.18e-06	9.1e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ARG2—prostate cancer	2.18e-06	9.1e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MDM2—prostate cancer	2.18e-06	9.08e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—SERPINE1—prostate cancer	2.17e-06	9.05e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ERBB2—prostate cancer	2.15e-06	8.96e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—LPL—prostate cancer	2.14e-06	8.95e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—LDHB—prostate cancer	2.14e-06	8.93e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PDGFRB—prostate cancer	2.13e-06	8.87e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CB—prostate cancer	2.12e-06	8.84e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP3A5—prostate cancer	2.1e-06	8.76e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ITGB3—prostate cancer	2.07e-06	8.64e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CXCL8—prostate cancer	2.04e-06	8.49e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA3—prostate cancer	2.03e-06	8.46e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PDHA1—prostate cancer	2.03e-06	8.46e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TCN2—prostate cancer	2.03e-06	8.46e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—UCP3—prostate cancer	2.03e-06	8.46e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB3—prostate cancer	2.01e-06	8.38e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGFR2—prostate cancer	2.01e-06	8.37e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDKN1B—prostate cancer	1.99e-06	8.3e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CASP3—prostate cancer	1.95e-06	8.13e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL2—prostate cancer	1.95e-06	8.12e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.94e-06	8.07e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.94e-06	8.07e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TERT—prostate cancer	1.93e-06	8.04e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CCND1—prostate cancer	1.9e-06	7.91e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CTNNB1—prostate cancer	1.88e-06	7.84e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.86e-06	7.74e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA4—prostate cancer	1.86e-06	7.74e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HIF1A—prostate cancer	1.84e-06	7.68e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MMP9—prostate cancer	1.84e-06	7.68e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDKN1A—prostate cancer	1.83e-06	7.66e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PTEN—prostate cancer	1.83e-06	7.64e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA2—prostate cancer	1.81e-06	7.54e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—LEP—prostate cancer	1.8e-06	7.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ABCG5—prostate cancer	1.79e-06	7.45e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.79e-06	7.45e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CAV1—prostate cancer	1.78e-06	7.43e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KDR—prostate cancer	1.76e-06	7.35e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EP300—prostate cancer	1.75e-06	7.28e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTA1—prostate cancer	1.74e-06	7.28e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTO1—prostate cancer	1.72e-06	7.2e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.72e-06	7.2e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NAT2—prostate cancer	1.72e-06	7.2e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SRC—prostate cancer	1.7e-06	7.08e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BAD—prostate cancer	1.68e-06	6.99e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PLCB2—prostate cancer	1.65e-06	6.9e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.65e-06	6.9e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—LRP2—prostate cancer	1.65e-06	6.9e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—VEGFA—prostate cancer	1.65e-06	6.9e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—STAT3—prostate cancer	1.64e-06	6.83e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CG—prostate cancer	1.62e-06	6.77e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—APC—prostate cancer	1.62e-06	6.77e-05	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—AKT1—prostate cancer	1.62e-06	6.77e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—P4HB—prostate cancer	1.62e-06	6.77e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGF—prostate cancer	1.6e-06	6.69e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IRS1—prostate cancer	1.6e-06	6.69e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.58e-06	6.58e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GSK3B—prostate cancer	1.56e-06	6.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.54e-06	6.41e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—INS—prostate cancer	1.54e-06	6.41e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MYC—prostate cancer	1.52e-06	6.35e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TGFB1—prostate cancer	1.52e-06	6.33e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MED12—prostate cancer	1.51e-06	6.31e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CREBBP—prostate cancer	1.5e-06	6.28e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GNG5—prostate cancer	1.5e-06	6.26e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGFR—prostate cancer	1.49e-06	6.21e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IGF1—prostate cancer	1.49e-06	6.2e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA3—prostate cancer	1.45e-06	6.03e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAP2K1—prostate cancer	1.44e-06	5.99e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CD—prostate cancer	1.43e-06	5.95e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SERPINE1—prostate cancer	1.41e-06	5.89e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KRAS—prostate cancer	1.41e-06	5.87e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—HPGDS—prostate cancer	1.38e-06	5.75e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MYC—prostate cancer	1.37e-06	5.73e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.37e-06	5.72e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—FGF2—prostate cancer	1.37e-06	5.7e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NOS3—prostate cancer	1.35e-06	5.62e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTT1—prostate cancer	1.34e-06	5.58e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ACHE—prostate cancer	1.34e-06	5.58e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.32e-06	5.52e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—JAK2—prostate cancer	1.31e-06	5.46e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CA—prostate cancer	1.29e-06	5.39e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.29e-06	5.37e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PRKACB—prostate cancer	1.28e-06	5.34e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MDM2—prostate cancer	1.28e-06	5.33e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.27e-06	5.28e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB2—prostate cancer	1.26e-06	5.26e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TP53—prostate cancer	1.25e-06	5.21e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CB—prostate cancer	1.24e-06	5.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA2—prostate cancer	1.21e-06	5.03e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL8—prostate cancer	1.19e-06	4.99e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDKN1B—prostate cancer	1.17e-06	4.87e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.15e-06	4.8e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CASP3—prostate cancer	1.14e-06	4.77e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL6—prostate cancer	1.14e-06	4.77e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL2—prostate cancer	1.14e-06	4.76e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.12e-06	4.69e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CCND1—prostate cancer	1.11e-06	4.64e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NQO1—prostate cancer	1.11e-06	4.64e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CTNNB1—prostate cancer	1.1e-06	4.6e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TH—prostate cancer	1.1e-06	4.57e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MMP9—prostate cancer	1.08e-06	4.51e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDKN1A—prostate cancer	1.08e-06	4.49e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTEN—prostate cancer	1.07e-06	4.48e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.07e-06	4.45e-05	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—AKT1—prostate cancer	1.05e-06	4.4e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GGT1—prostate cancer	1.03e-06	4.31e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EP300—prostate cancer	1.02e-06	4.28e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NCOA1—prostate cancer	1.02e-06	4.24e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP19A1—prostate cancer	1e-06	4.18e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SRC—prostate cancer	9.96e-07	4.16e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—VEGFA—prostate cancer	9.7e-07	4.05e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—RXRA—prostate cancer	9.67e-07	4.03e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—STAT3—prostate cancer	9.61e-07	4.01e-05	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—AKT1—prostate cancer	9.52e-07	3.97e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—COMT—prostate cancer	9.31e-07	3.89e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTP1—prostate cancer	9.27e-07	3.87e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ITPR1—prostate cancer	9.12e-07	3.81e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MYC—prostate cancer	8.93e-07	3.73e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFB1—prostate cancer	8.91e-07	3.72e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGFR—prostate cancer	8.73e-07	3.64e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TYMS—prostate cancer	8.62e-07	3.6e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTM1—prostate cancer	8.52e-07	3.55e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—LPL—prostate cancer	8.36e-07	3.49e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KRAS—prostate cancer	8.25e-07	3.44e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP1A1—prostate cancer	8.08e-07	3.37e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ERCC2—prostate cancer	8.01e-07	3.34e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CA—prostate cancer	7.58e-07	3.16e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—MTHFR—prostate cancer	7.53e-07	3.14e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PPARA—prostate cancer	7.39e-07	3.08e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TP53—prostate cancer	7.33e-07	3.06e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CAV1—prostate cancer	6.94e-07	2.9e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL6—prostate cancer	6.71e-07	2.8e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CG—prostate cancer	6.33e-07	2.64e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AKT1—prostate cancer	6.19e-07	2.58e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—INS—prostate cancer	5.99e-07	2.5e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CREBBP—prostate cancer	5.86e-07	2.45e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CD—prostate cancer	5.56e-07	2.32e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NOS3—prostate cancer	5.25e-07	2.19e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.85e-07	2.02e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTGS2—prostate cancer	4.8e-07	2e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTEN—prostate cancer	4.19e-07	1.75e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—EP300—prostate cancer	3.99e-07	1.67e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.95e-07	1.23e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AKT1—prostate cancer	2.41e-07	1.01e-05	CbGpPWpGaD
